[ Price : $8.95]
FDA reviews the first-year accomplishments and future plans for the multi-country Generic Drug Cluster.[ Price : $8.95]
Researchers in the U.S. and Australia call for an update to transparency policies so that all individual participant data supporti...[ Price : $8.95]
FDA sets 5/23/23 as the target PDUFA action date for its review of ImmunityBios N-803 to treat some bladder cancers.[ Price : $8.95]
FDA accepts for review a Lexicon Pharmaceuticals NDA resubmission for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhib...[ Price : $8.95]
Senate leaders introduce the Cannabis Administration and Opportunity Act.[ Price : $8.95]
FDA grants breakthrough therapy designation to Vertex VX-548 for some acute and neuropathic pain indications.[ Price : $8.95]
FDA warns Dr. Daniel Goodman about objectionable conditions in a clinical trial at his San Francisco, CA-based Goodman Eye Center.[ Price : $8.95]
FDA publishes a guidance to help drug sponsors who are planning to conduct clinical studies in neonatal populations.